Related Experiment Video
Updated: Jun 23, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Circulating markers of biliary malignancy: opportunities in proteomics?
Glenn K Bonney1, Rachel A Craven, Raj Prasad
1Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK.
The Lancet. Oncology
|February 2, 2008
Summary
Proteomics offers a promising avenue for discovering early diagnostic markers for cholangiocarcinoma, a challenging liver cancer. This approach analyzes proteins to identify biomarkers, potentially improving patient survival rates.
Area of Science:
- Biochemistry
- Oncology
- Biomarker Discovery
Background:
- Cholangiocarcinoma (CCA) is a primary liver cancer with increasing incidence and poor prognosis.
- Early diagnosis is crucial for surgical resection, the only potential cure, but current methods lack sensitivity and specificity.
- Patients with primary sclerosing cholangitis face a higher risk of developing CCA.
Purpose of the Study:
- To review the current status and potential of proteomic-based approaches for biomarker discovery in cholangiocarcinoma.
- To highlight the importance of identifying sensitive and specific early diagnostic markers for CCA.
- To discuss how proteomics can aid in understanding CCA pathogenesis.
Main Methods:
- Review of current literature on proteomic-based approaches in cholangiocarcinoma research.
- Analysis of technological and bioinformatics advancements enhancing proteomic studies.
- Examination of the role of proteomics in identifying biomarkers from various biological samples.
Main Results:
- Proteomic approaches analyze the complete set of proteins (proteome) in cells, tissues, or fluids.
- Proteomics complements genomics by quantitatively and qualitatively assessing functional units, including post-translational modifications.
- Advances in technology and bioinformatics have significantly improved the utility of proteomics for biomarker discovery.
Conclusions:
- Proteomic-based strategies hold substantial promise for discovering novel biomarkers for early cholangiocarcinoma detection.
- Improved biomarkers are essential to address the limited survival rates associated with late diagnosis and lack of alternative treatments.
- Further research utilizing proteomics can enhance the understanding of CCA pathogenesis and lead to improved clinical outcomes.
